People with type 2 diabetes are at a high risk of developing severe health complications such as heart attacks, strokes, heart failure, and advanced kidney disease. However, recent research from ...
A new study has examined a large sample of privately insured patients with obesity and found that use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as anti-obesity medications more than ...
The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27.